PRLD — Prelude Therapeutics Inc

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1678660 ·
Last close
$3.32
Market Cap
$216.05M
52W High
$6.83
52W Low
$1.29
ADV30
376,310
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 5,647,000 — -14,265,000 -12,544,000 175,485,000 23,412,000 51,349,000
Jun 2026 5,704,000 — -15,454,000 -13,921,000 189,363,000 26,329,000 55,630,000
Mar 2026 4,580,000 — -14,177,000 -10,385,000 119,642,000 21,756,000 59,459,000
Dec 2025 5,640,000 — -17,348,000 -16,457,000 141,315,000 35,256,000 72,678,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-33,255,000
Investing CF
$-77,252,000
Financing CF
$110,445,000
CapEx
$-67,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.94
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-707,367,000
Inventory
—
Receivables
—
ST Investments
$125,428,000
EBIT TTM
$-67,397,000
Pretax Income TTM
$-60,488,000
Interest Exp TTM
—
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$22,424,000
EBITDA
$-64,510,000
Free Cash Flow
$-13,844,625
Enterprise Value
$338,639,712
Total Cash
$151,756,992
Total Debt
$17,650,000
Shares Out
65,075,350
Trailing EPS
$-0.73
Book Value
$1.30
ROE
-57.7%
ROA
-27.2%
Div Yield
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 12,140,000 -104,566,000 -99,498,000 141,315,000 72,678,000 68,637,000 -56,302,000
Dec 2024 7,000,000 -139,714,000 -127,173,000 175,515,000 44,056,000 131,459,000 -102,888,000
Dec 2023 0 -132,277,000 -121,832,000 277,665,000 40,575,000 237,090,000 -107,063,000
Dec 2022 0 -123,540,000 -115,438,000 220,500,000 25,063,000 195,437,000 -83,729,000

TTM Snapshot

Revenues TTM
$22,424,000
NetIncome TTM
$-60,488,000
OpCashFlow TTM
—
Assets (Latest)
$189,363,000
Forward EPS
$-0.75

Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)

max pain strike: $5.00 · spot: $3.30 · call volume: 24 · put volume: 30

Peers — same industry

TickerNameMarket CapLastDaily %
LAB STANDARD BIOTOOLS INC. $212.95M $0.54 —
NGEN NERVGEN PHARMA CORP. $210.74M $1.96 —
KROS Keros Therapeutics, Inc. $221.95M $11.31 —
ACIU AC Immune SA $209.79M $2.11 —
IMRX Immuneering Corp $224.08M $3.46 —

News headlines (Yahoo Finance, 1h cache)

Prelude Therapeutics Incorporated (PRLD) Reports Q3 Loss, Beats Revenue Estimates
2026-11-16 12:15 · Yahoo
Prelude Therapeutics Incorporated (PRLD) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
2026-11-04 14:00 · Yahoo
Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option
2026-10-23 03:02 · Yahoo
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
2026-10-16 20:01 · Yahoo
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
2026-10-16 12:35 · Yahoo
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Brea
2026-10-13 11:01 · Yahoo
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-11 11:01 · Yahoo
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
2026-09-10 11:01 · Yahoo
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
2026-07-17 16:00 · Yahoo
Goldman Sachs Initiates Coverage of Prelude Therapeutics (PRLD)
2026-05-31 10:55 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.